HUP0105392A2 - Megerősített vakcinák - Google Patents
Megerősített vakcinákInfo
- Publication number
- HUP0105392A2 HUP0105392A2 HU0105392A HUP0105392A HUP0105392A2 HU P0105392 A2 HUP0105392 A2 HU P0105392A2 HU 0105392 A HU0105392 A HU 0105392A HU P0105392 A HUP0105392 A HU P0105392A HU P0105392 A2 HUP0105392 A2 HU P0105392A2
- Authority
- HU
- Hungary
- Prior art keywords
- ige
- immunogenic polypeptides
- nucleic acid
- cheese
- acid molecules
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 230000002163 immunogen Effects 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 241000124008 Mammalia Species 0.000 abstract 3
- 239000000463 material Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 235000013351 cheese Nutrition 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
A tal lm ny elj r sokkal és anyagokkal foglalkozik, amelyek érintettekkül"nb"ző betegségek, péld ul fertőzések vagy IgE-vel kapcsolatosbetegségek kezelésében. A tal lm ny pontosabban olyan elj r sokra ésanyagokra vonatkozik, amelyeket emlős"k vakcin l s ra lehet alkalmaznifajlagos saj t vagy nem saj t antigének ellen. ═gy péld ul az ittleírt elj r sokat és anyagokat lehet alkalmazni IgE antitestek hatsainak cs"kkentésére valamely emlősben a teljes és receptor-k"t"tt IgEantitestek mennyiségének cs"kkentésével az emlősben. Ezen kívül a tallm ny vakcina konjug tumokat, immunogén polipeptideket, immunogénpolipeptideket hódoló nukleinsav molekul kat és immunogénpolipeptidelcet kódoló nukleinsav molekul kat tartalmazó gazdasejteketnyújt, tov bbi elj r sokat nyújt vakcina konjug tumok, immunogénpolipeptidek és immunogén polipeptideket kódoló nukleinsav molekul kelő llít s ra. A tal lm ny tov bb olyan IgE vakcin t biztosít, amelyanti-saj t IgE v laszt induk lhat emlős"kben. Ó
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10665298P | 1998-11-02 | 1998-11-02 | |
US09/401,636 US6913749B2 (en) | 1998-11-02 | 1999-09-22 | Immunogenic polypeptides for inducing anti-self IgE responses |
PCT/SE1999/001896 WO2000025722A2 (en) | 1998-11-02 | 1999-10-21 | ENHANCED VACCINES COMPRISING SELF AND NON-SELF IgE PORTIONS OR DIMERIC ANTIGENS |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0105392A2 true HUP0105392A2 (hu) | 2002-04-29 |
HUP0105392A3 HUP0105392A3 (en) | 2008-04-28 |
Family
ID=26803871
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0105392A HUP0105392A3 (en) | 1998-11-02 | 1999-10-21 | Enhanced vaccines |
Country Status (18)
Country | Link |
---|---|
US (3) | US6913749B2 (hu) |
EP (1) | EP1135158B1 (hu) |
JP (2) | JP4205861B2 (hu) |
KR (1) | KR100559918B1 (hu) |
AT (1) | ATE314087T1 (hu) |
AU (1) | AU771889B2 (hu) |
CA (1) | CA2348756A1 (hu) |
DE (1) | DE69929240T2 (hu) |
DK (1) | DK1135158T3 (hu) |
ES (1) | ES2255325T3 (hu) |
HK (1) | HK1042844A1 (hu) |
HU (1) | HUP0105392A3 (hu) |
IL (1) | IL142582A0 (hu) |
NO (1) | NO20012135L (hu) |
NZ (1) | NZ511079A (hu) |
PL (1) | PL348611A1 (hu) |
PT (1) | PT1135158E (hu) |
WO (1) | WO2000025722A2 (hu) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7658101A (en) * | 2000-07-28 | 2002-02-13 | Cytos Biotechnology Ag | Compositions for inducing self-specific anti-ige antibodies and uses thereof |
EP2065052A3 (en) * | 2000-08-30 | 2009-08-19 | Pfizer Products Inc. | Anti-IgE vaccines |
JP2004508028A (ja) * | 2000-09-06 | 2004-03-18 | ファーメクサ エイ/エス | IgEをダウン−レギュレートさせる方法 |
US20040071671A1 (en) | 2001-02-20 | 2004-04-15 | Leturcq Didier J. | Cell therapy method for the treatment of tumors |
DK2016930T3 (en) | 2001-02-20 | 2014-12-08 | Janssen Pharmaceuticals Inc | CD8 cell suspension for use in the treatment of melanomas |
DE60233231D1 (de) * | 2001-05-15 | 2009-09-17 | Ortho Mcneil Janssen Pharm | Ex-vivo-priming zur erzeugung cd40-ligand spezifischer zytotoxischer t-lymphozyten zur behandlung von autoimmun- und allergischen erkrankungen |
JP2003047482A (ja) * | 2001-05-22 | 2003-02-18 | Pfizer Prod Inc | 非アナフィラキシー誘発性IgEワクチン |
EP1504102A2 (en) | 2002-05-21 | 2005-02-09 | Resistentia Pharmaceuticals AB | Chimeric ige polypeptides and host cells |
DE60324816D1 (de) * | 2002-09-05 | 2009-01-02 | Resistentia Pharmaceuticals Ab | Impfstoffe gegen allergien |
US20080118524A1 (en) * | 2006-10-20 | 2008-05-22 | Stefan Persson | Anti-IgE Vaccines |
WO2008153761A1 (en) * | 2007-05-23 | 2008-12-18 | Mastcell Pharmaceuticals, Inc. | Methods |
WO2009142772A2 (en) | 2008-05-23 | 2009-11-26 | Mastcell Pharmaceuticals, Inc. | Methods and treatment for allergies and inflammation associated with gastrointestinal diseases |
KR101644221B1 (ko) | 2008-12-09 | 2016-07-29 | 화이자 백신스 엘엘씨 | IgE CH3 펩티드 백신 |
EP2942061A3 (en) | 2010-06-07 | 2016-01-13 | Pfizer Vaccines LLC | Ige ch3 peptide vaccine |
US9187553B2 (en) * | 2012-01-25 | 2015-11-17 | Swey-Shen Chen | Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold |
WO2013156054A1 (en) * | 2012-04-16 | 2013-10-24 | Universität Stuttgart | The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity |
CN104395337A (zh) * | 2012-06-18 | 2015-03-04 | 日本全药工业株式会社 | IgE肽疫苗 |
JP2019509059A (ja) | 2016-02-16 | 2019-04-04 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 変異型キヌレニナーゼ遺伝子を有する非ヒト動物 |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4767842A (en) | 1973-05-07 | 1988-08-30 | The Ohio State University | Antigenic modification of polypeptides |
US5698201A (en) | 1973-05-07 | 1997-12-16 | The Ohio State University | Method for treatment of antigenically modified polypeptides |
US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
US4483793A (en) | 1982-10-04 | 1984-11-20 | The Regents Of The University Of California | Dimeric oligopeptides as heptenic epitopic sites for hepatitis |
US4782137A (en) | 1984-01-24 | 1988-11-01 | Immunex Corporation | Synthesis of protein with an identification peptide, and hybrid polypeptide incorporating same |
US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5175385A (en) | 1987-09-03 | 1992-12-29 | Ohio University/Edison Animal Biotechnolgy Center | Virus-resistant transgenic mice |
GB8727045D0 (en) | 1987-11-19 | 1987-12-23 | Research Corp Ltd | Immunoglobulin e competitor |
US5254671A (en) * | 1990-04-27 | 1993-10-19 | Tanox Biosystems, Inc. | Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor |
DE122006000007I1 (de) | 1987-12-31 | 2006-04-27 | Tanox Biosystems Inc | Antigene epitope, die sich ausschlisslich auf ige-tragenden B-Lymphocyten befinden. |
JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル. モリソン,シェリー | ドメイン‐変性不変部を有する抗体 |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
GB8910263D0 (en) | 1989-05-04 | 1989-06-21 | Ciba Geigy Ag | Monoclonal antibodies specific for an immunoglobulin isotype |
US5955076A (en) | 1989-06-15 | 1999-09-21 | Peptide Therapeutics Limited | Immunoactive peptides and antibodies and their use in anti-allergy treatment |
GB8913737D0 (en) | 1989-06-15 | 1989-08-02 | Univ Birmingham | A novel anti-allergy treatment |
JPH04506662A (ja) | 1989-07-14 | 1992-11-19 | アメリカン・サイアナミド・カンパニー | 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー |
US5733553A (en) | 1989-09-29 | 1998-03-31 | Talwar; Gursaran Prasad | Recombinant birth control vaccine |
CA2074089C (en) | 1990-01-23 | 2001-04-10 | Tse-Wen Chang | Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor |
DK0605410T3 (da) | 1990-05-25 | 1995-12-04 | Peptide Therapeutics Ltd | Immunodiagnostisk assay for rheumatoid arthritis |
US5196197A (en) | 1990-08-29 | 1993-03-23 | National Institute Of Immunology | Reversible fertility control for prevention of pregnancy in females |
AU647566B2 (en) * | 1990-12-13 | 1994-03-24 | Immunex Corporation | Leukemia inhibitory factor receptors |
SE9102808L (sv) * | 1991-09-26 | 1993-03-27 | Lars T Hellman Inst F Immunolo | Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner |
US5837686A (en) | 1991-11-25 | 1998-11-17 | Peptide Therapeutics Limited | Peptides and antibodies for treatment of rheumatoid arthritis |
AU4955593A (en) | 1992-09-01 | 1994-03-29 | United Nations Industrial Development Organization | Peptide showing cross-reactivity with the anti-hepatitis b surface antigen antiserum |
US6099846A (en) | 1992-10-14 | 2000-08-08 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of B cell lymphoma and tumor resistance using idiotype/cytokine conjugates |
US5762931A (en) | 1992-12-31 | 1998-06-09 | National Institute Of Immunology | Anti-cancer utility of HCG vaccines |
US5532142A (en) * | 1993-02-12 | 1996-07-02 | Board Of Regents, The University Of Texas System | Method of isolation and purification of fusion polypeptides |
US5552537A (en) * | 1993-03-24 | 1996-09-03 | The Regents Of The University Of California | IgE isoforms and methods of use |
US5501855A (en) | 1993-09-02 | 1996-03-26 | Talwar; Gursaran P. | Neem oil as a male contraceptive |
DK96493D0 (da) * | 1993-08-26 | 1993-08-26 | Mouritsen Og Elsner Aps | Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden |
US5874085A (en) * | 1993-11-10 | 1999-02-23 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Vaccine for enhanced production of IgA antibodies |
FR2715304B1 (fr) | 1994-01-26 | 1996-04-26 | Merieux Serums Vaccins Pasteur | Vaccin anti-allergique. |
EP0811016A1 (en) | 1994-03-28 | 1997-12-10 | United Biomedical, Inc. | Synthetic peptide based immunogens for the treatment of allergy |
US5651981A (en) * | 1994-03-29 | 1997-07-29 | Northwestern University | Cationic phospholipids for transfection |
CA2203165A1 (en) | 1994-10-25 | 1996-05-02 | United Biomedical, Inc. | Synthetic ige membrane anchor peptide immunogens for the treatment of allergy |
GB9422294D0 (en) | 1994-11-04 | 1994-12-21 | Peptide Therapeutics Ltd | Peptides for anti-allergy treatment |
US6949244B1 (en) | 1995-12-20 | 2005-09-27 | The Board Of Trustees Of The University Of Kentucky | Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof |
JPH08333390A (ja) | 1995-04-07 | 1996-12-17 | Hoechst Japan Ltd | ペプチド及びそれからなる自己免疫疾患治療剤 |
CA2227198A1 (en) | 1995-07-17 | 1997-02-06 | Peptide Therapeutics Limited | Cysteine protease inhibitors for use in treatment of ige mediated allergic diseases |
ZA966075B (en) | 1995-07-27 | 1998-01-19 | Genentech Inc | Protein formulation. |
US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
WO1997031948A1 (en) | 1996-03-01 | 1997-09-04 | Novartis Ag | Peptide immunogens for vaccination against and treatment of allergy |
AU730477B2 (en) | 1996-08-05 | 2001-03-08 | President And Fellows Of Harvard College | MHC binding peptide oligomers and methods of use |
PL194221B1 (pl) | 1997-04-15 | 2007-05-31 | Pharmexa As | Zmodyfikowana cząsteczka ludzkiego TNFalfa, dimery, oligomery lub multimery zmodyfikowanej cząsteczki ludzkiego TNFalfa, wyizolowana cząsteczka DNA, wektor, wektor ekspresyjny, komórka gospodarza, sposób wytwarzania zmodyfikowanej cząsteczki ludzkiego TNFalfa, szczepionki przeciwko TNFalfa oraz zastosowanie przynajmniej jednej zmodyfikowanej cząsteczki ludzkiego TNFalfa |
US6165476A (en) * | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
US5891432A (en) * | 1997-07-29 | 1999-04-06 | The Immune Response Corporation | Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same |
EP1279401B1 (en) | 1997-09-05 | 2008-01-09 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
AU3291099A (en) | 1998-02-11 | 1999-08-30 | Maxygen, Inc. | Genetic vaccine vector engineering |
US6299875B1 (en) | 1998-06-04 | 2001-10-09 | Panacea Pharmaceuticals, Llc | Methods to block IGE binding to cell surface receptors of mast cells |
TWI227241B (en) | 1998-06-20 | 2005-02-01 | United Biomedical Inc | IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate |
HUP0103976A3 (en) | 1998-10-05 | 2008-04-28 | Pharmexa As | Novel methods for therapeutic vaccination |
BR9915771A (pt) | 1998-11-30 | 2001-12-26 | Cytos Biotechnology Ag | Apresentação molecular ordenada de antìgenos,processo de preparação e utilização |
GB9908533D0 (en) | 1999-04-14 | 1999-06-09 | Novartis Ag | Organic compounds |
AU777952B2 (en) | 1999-04-23 | 2004-11-04 | Pharmexa A/S | Method for down-regulating IL5 activity |
AU7658101A (en) | 2000-07-28 | 2002-02-13 | Cytos Biotechnology Ag | Compositions for inducing self-specific anti-ige antibodies and uses thereof |
JP2004508028A (ja) | 2000-09-06 | 2004-03-18 | ファーメクサ エイ/エス | IgEをダウン−レギュレートさせる方法 |
JP2004537991A (ja) | 2001-06-15 | 2004-12-24 | タノックス インコーポレーテッド | アレルギー及び喘息治療用Fcε融合タンパク質 |
-
1999
- 1999-09-22 US US09/401,636 patent/US6913749B2/en not_active Expired - Fee Related
- 1999-10-21 CA CA002348756A patent/CA2348756A1/en not_active Abandoned
- 1999-10-21 AT AT99963705T patent/ATE314087T1/de not_active IP Right Cessation
- 1999-10-21 ES ES99963705T patent/ES2255325T3/es not_active Expired - Lifetime
- 1999-10-21 NZ NZ511079A patent/NZ511079A/en not_active IP Right Cessation
- 1999-10-21 AU AU20081/00A patent/AU771889B2/en not_active Ceased
- 1999-10-21 PT PT99963705T patent/PT1135158E/pt unknown
- 1999-10-21 HU HU0105392A patent/HUP0105392A3/hu not_active Application Discontinuation
- 1999-10-21 WO PCT/SE1999/001896 patent/WO2000025722A2/en active IP Right Grant
- 1999-10-21 PL PL99348611A patent/PL348611A1/xx not_active Application Discontinuation
- 1999-10-21 DK DK99963705T patent/DK1135158T3/da active
- 1999-10-21 DE DE69929240T patent/DE69929240T2/de not_active Expired - Lifetime
- 1999-10-21 JP JP2000579167A patent/JP4205861B2/ja not_active Expired - Fee Related
- 1999-10-21 KR KR1020017005276A patent/KR100559918B1/ko not_active IP Right Cessation
- 1999-10-21 EP EP99963705A patent/EP1135158B1/en not_active Expired - Lifetime
- 1999-10-21 IL IL14258299A patent/IL142582A0/xx not_active IP Right Cessation
-
2001
- 2001-04-30 NO NO20012135A patent/NO20012135L/no unknown
-
2002
- 2002-03-26 HK HK02102312A patent/HK1042844A1/xx not_active IP Right Cessation
- 2002-06-19 US US10/176,664 patent/US7459158B2/en not_active Expired - Fee Related
-
2003
- 2003-09-29 US US10/673,594 patent/US20040076625A1/en not_active Abandoned
-
2005
- 2005-09-07 JP JP2005258648A patent/JP4188353B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP4205861B2 (ja) | 2009-01-07 |
PT1135158E (pt) | 2006-05-31 |
US20010038843A1 (en) | 2001-11-08 |
KR20010089364A (ko) | 2001-10-06 |
WO2000025722A3 (en) | 2000-10-12 |
ES2255325T3 (es) | 2006-06-16 |
US6913749B2 (en) | 2005-07-05 |
IL142582A0 (en) | 2002-03-10 |
NO20012135L (no) | 2001-06-25 |
DE69929240D1 (de) | 2006-02-02 |
EP1135158B1 (en) | 2005-12-28 |
DK1135158T3 (da) | 2006-05-15 |
AU771889B2 (en) | 2004-04-08 |
DE69929240T2 (de) | 2006-08-31 |
PL348611A1 (en) | 2002-06-03 |
JP2002531064A (ja) | 2002-09-24 |
US20030031663A1 (en) | 2003-02-13 |
US20040076625A1 (en) | 2004-04-22 |
JP2006068015A (ja) | 2006-03-16 |
CA2348756A1 (en) | 2000-05-11 |
WO2000025722A2 (en) | 2000-05-11 |
JP4188353B2 (ja) | 2008-11-26 |
EP1135158A2 (en) | 2001-09-26 |
US7459158B2 (en) | 2008-12-02 |
AU2008100A (en) | 2000-05-22 |
ATE314087T1 (de) | 2006-01-15 |
KR100559918B1 (ko) | 2006-03-13 |
NO20012135D0 (no) | 2001-04-30 |
NZ511079A (en) | 2003-08-29 |
HK1042844A1 (en) | 2002-08-30 |
HUP0105392A3 (en) | 2008-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0105392A2 (hu) | Megerősített vakcinák | |
ES8801319A1 (es) | Un metodo para la deteccion de anticuerpos especificos de un virus lav en un fluido biologico. | |
NZ512574A (en) | Novel streptococcus antigens useful as vaccines | |
HUP9901546A2 (hu) | Helicobacter pylori antigének és vakcinakészítmények | |
FI932678A (fi) | Pao alfavirus baserande dna expressionssystem | |
MY103182A (en) | Vaccines against acquired immune deficiency syndrome. | |
HUP0302532A2 (hu) | Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások | |
BR9708387A (pt) | Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada. | |
DK0942983T3 (da) | Streptococcus pneumoniae-antigener og -vacciner | |
BR9711457A (pt) | Compostos e processo para o tratamento e diagnóstico de infecções micobacterianas. | |
DK0431541T3 (da) | Toxoplasma gondii-antigener, deres fremstilling og deres anvendelse | |
HUP9801223A2 (hu) | Eljárás specifikus antigénekre adott antitest válasz fokozására interleukin-10-zel | |
NZ500540A (en) | Purified proteins, fusion proteins, recombinant vector, vaccine, kit, comprising proteins from Actinobacillus pleuropneumoniae | |
HUP9702359A2 (hu) | Monoklonális antitest, eljárás monoklonális antitest előállítására, valamint a monoklonális antitestet tartalmazó gyógyászati készítmény és diagnosztikai reagens | |
EP0306219A3 (en) | Novel hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids | |
ATE294868T1 (de) | Impfstoff gegen streptokokkeninfektionen der gruppe a | |
HUP0302566A2 (hu) | Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására | |
DE3889581D1 (de) | Monoklonale Antikörper gegen spezifische antigene Regionen des humanen Immundefizienzvirus und Methoden zur Verwendung. | |
ATE124420T1 (de) | Impfstoffe und testsätze für haemophilus influenzae. | |
SE9903534L (sv) | Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning | |
AP2368A (en) | Novel expression vectors and uses thereof. | |
OA09653A (en) | Rubella peptides | |
FI911973A0 (fi) | Traodaktigt hemagglutinin av b. pertussis-bacill. | |
GB2227936A (en) | Vaccine against brucella abortus | |
NO175846C (no) | Fremgangsmåte for å oppnå et immunogen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC4A | Lapse of provisional application due to refusal |